Purple Biotech (PPBT) has released an update.
Purple Biotech, a clinical-stage company focused on oncology therapies, has received a 180-day extension from Nasdaq to meet the minimum bid price requirement for continued listing. During this period, the company’s share price must close at $1.00 or higher for at least 10 consecutive business days before January 21, 2025. The company’s shares will remain listed and traded on the Nasdaq Capital Market, with potential further action planned to address the compliance challenge.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
